

Special Issue

Cell-Free DNA for the Management of Lymphoma

Message from the Guest Editor

The journal *Pharmaceuticals* is planning to publish a Special Issue covering the topic “**Cell-free DNA for the Management of Lymphoma**” and we are inviting you to contribute an article to this volume. Lymphoma is an extremely heterogeneous disease with several distinct clinical, pathological, genetic, and molecular features. Routine diagnostic biopsy might not reflect the overall intratumoral genetic heterogeneity of lymphomas. The convenience of cell-free DNA (cfDNA) encompasses decreased risks associated with blood collection compared to tissue biopsy, the freedom to perform numerous sampling events over time, reasonable expense and possibly more lymphoma-representative sampling events than that offered by the spatial heterogeneity of tissue biopsy. In the present Special Issue, we would like you to share your contributions to the advances and opportunities in this booming field of cfDNA tools. We also wish to assess situations where cfDNA monitoring might show promising progress toward wider acceptance in lymphoma management and discuss practical concerns that remain to be explored.

Guest Editor

Dr. Vincent Camus

Department of Hematology and INSERM U1245, Centre Henri Becquerel, Rouen, France

Deadline for manuscript submissions

closed (28 January 2022)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/47037

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)